Suggested remit: To appraise the clinical and cost effectiveness of talazoparib with enzalutamide within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer in people who have not had prior systemic treatment.
Please note the company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps.
 
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 4004

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 August 2023 Suspended. Please note the company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps.
31 July 2023 - 04 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1234
10 July 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early September 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
04 November 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Please note that following on from information received from the company, the timelines for this appraisal will be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any developments and will update interested parties as and when the situation changes.
02 September 2022 - 30 September 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
02 September 2022 In progress. Scoping commenced
05 August 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late November 2022.
12 April 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.

For further information on our processes and methods, please see our CHTE processes and methods manual